Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Non Operating Income: 2019-2025

Historic Non Operating Income for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $10.3 million.

  • Kymera Therapeutics' Non Operating Income rose 7.36% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 13.51%. This contributed to the annual value of $37.8 million for FY2024, which is 103.45% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Non Operating Income stood at $10.3 million, which was up 30.25% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Non Operating Income peaked at $10.3 million during Q3 2025, and registered a low of $55,000 during Q3 2021.
  • Over the past 3 years, Kymera Therapeutics' median Non Operating Income value was $8.8 million (recorded in 2025), while the average stood at $7.6 million.
  • Per our database at Business Quant, Kymera Therapeutics' Non Operating Income tumbled by 70.16% in 2021 and then soared by 3,905.32% in 2022.
  • Kymera Therapeutics' Non Operating Income (Quarterly) stood at $94,000 in 2021, then surged by 3,905.32% to $3.8 million in 2022, then spiked by 31.31% to $4.9 million in 2023, then spiked by 102.33% to $10.0 million in 2024, then increased by 7.36% to $10.3 million in 2025.
  • Its Non Operating Income stands at $10.3 million for Q3 2025, versus $7.9 million for Q2 2025 and $8.8 million for Q1 2025.